Don’t quarantine your wealth. Do this instead…

On April 1, InvestorPlace analyst Matt McCall is revealing details about a little-known corner of the markets that could hand you a fortune during a bear market. To prove it, he’ll share the name of his #1 bear market stock.

Wed, April 1 at 7:00PM ET
 
 
 
 

6 Biotechnology Stocks to Buy Now

TSRO, MNOV, EBS, VNDA, AMBI, ADXS improve in weekly rankings

Six biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

TESARO, Inc.’s (TSRO) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Tesaro develops and commercializes cancer therapeutics and supportive care products. For more information, get Portfolio Grader’s complete analysis of TSRO stock.

MediciNova, Inc. (MNOV) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

This week, Emergent BioSolutions Inc. (EBS) pushes up from a C to a B rating. Emergent BioSolutions develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. For more information, get Portfolio Grader’s complete analysis of EBS stock.

The rating of Vanda Pharmaceuticals (VNDA) moves up this week, rising from a C to a B. Vanda Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. For more information, get Portfolio Grader’s complete analysis of VNDA stock.

Ambit Biosciences Corp. (AMBI) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Advaxis, Inc.’s (ADXS) ratings are looking better this week, moving up to a B from last week’s C. For more information, get Portfolio Grader’s complete analysis of ADXS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2014/12/6-biotechnology-stocks-to-buy-now-tsro-mnov-ebs/.

©2020 InvestorPlace Media, LLC